

February 6, 2024



# Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.

## Conference Details:

Oppenheimer 34th Annual Healthcare Life Sciences Conference

Date: February 13-14, 2024

Location: Virtual

TD Cowen 44th Annual Health Care Conference

Date: March 3-6, 2024

Location: Boston

Barclays 26th Annual Global Healthcare Conference

Date: March 12-14, 2024

Location: Miami

Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the company's website at [www.sutro.bio.com](http://www.sutro.bio.com). Archived replays will be available for at least 30 days after the event.

## About Sutro Biopharma

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro's fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro's continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @SutroBio, or visit [www.sutro.bio.com](http://www.sutro.bio.com).

## Contact

Emily White

Sutro Biopharma

(650) 823-7681

[ewhite@sutro.bio.com](mailto:ewhite@sutro.bio.com)



Source: Sutro Biopharma, Inc.